

**Date: February 14, 2025**

To  
BSE Ltd.  
P. J. Towers  
Dalal Street,  
Mumbai - 400 001.

**BSE Scrip Code: 524444**

**Sub:-** Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024

Dear Sir,

In furtherance to the financial results and outcome of the Board Meeting submitted by the Company on February 14, 2025, we are submitting herewith the Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024, in compliance of the SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024.

Kindly take the same on your records and oblige.

Thanking You,

Yours faithfully,

**FOR, EVEXIA LIFECARE LIMITED**

**JAYESH RAICHANDBHAI THAKKAR**  
**MANAGING DIRECTOR**  
**(DIN: 01631093)**

**INTEGRATED FILING (FINANCIAL) FOR THE QUARTER AND NINE MONTHS ENDED  
DECEMBER 31, 2024**

- A. Financial Results:** Attached as Annexure -1.
- B. Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc.:** Attached as Annexure -2.
- C. Format for disclosing outstanding default on loans and debt securities:** Not Applicable
- D. Format for disclosure of related party transactions (applicable only for half yearly fillings i.e. 2<sup>nd</sup> and 4<sup>th</sup> quarter):** Not Applicable for this quarter
- E. Statement on impact of audit qualifications (for audit report with modified opinion) submitted along-with annual audited financial results (standalone and consolidated separately) (applicable only for annual filling i.e. 4<sup>th</sup> quarter):** Not Applicable for this Quarter



Date:- February 14,2025

To  
BSE Ltd.  
P. J. Towers  
Dalal Street,  
Mumbai - 400 001

**BSE Scrip Code: 524444**

**Sub: - Outcome and Disclosure of Board Meeting under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir,

We wish to inform you that at the meeting of the Board of Directors of the Company held today, the following businesses were transacted inter alia:-

1. In terms of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Board of Directors of the Company had considered and approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended on December 31, 2024.
2. Took a note on resignation of Ms. Payal Gajjar (DIN-08745777) with effect from closure of business hours of January 07,2025 duly disclosed on BSE vide disclosure dated January 07,2025.

The details required under Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD1 /P/CIR /2023/123 dated July 13, 2023 were enclosed vide disclosure dated January 07,2025

The Board Meeting started at 07:30 p.m. and ended at 08:15 p.m.

Kindly take the same on the record and oblige.

Yours faithfully,

**For, EVEXIA LIFECARE LIMITED**

JAYESHKUMAR  
RAICHANDBHAI  
THAKKAR

Digitally signed by JAYESHKUMAR RAICHANDBHAI THAKKAR  
DN: c=IN, o=Personal, ou=0645,  
serialNumber=D770246F02462379416348954888,  
2.5.4.20=7481198756081ee05eac21d3c95de93c21b8f481b44  
c22f0f91f8e7e484, postalCode=390007, st=Gujrat,  
serialNumber=84c4e52077a61188459f8163a36042034a270a  
0054a7746756424400830, cn=JAYESHKUMAR RAICHANDBHAI  
THAKKAR  
Date: 2025.02.14 20:20:23 +05'30'

**JAYESH RAICHANDBHAI THAKKAR**  
**MANAGING DIRECTOR**  
**DIN: 01631093**

**Reg. Off. :** Tundav Anjesar Raod, Vill. Tundav, Tal.: Savli, Vadodara - 391 775

**Corporate Office :** 9th Floor, Galav Chambers, Sayajigunj, Vadodara-390 020. **Ph :** +91 265 2361100 / 2200

**CIN :** L23100GJ1990PLC014692 **Email :** info@evexialifecare.com **Web.:** www.evexialifecare.com

**Limited Review Report on Un-Audited Standalone Quarterly Financial Results of Evexia Lifecare Limited pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 for the Quarter ended on December 31, 2024.**

**To**  
**Board of Directors of**  
**Evexia Lifecare Limited**

**INTRODUCTION**

1. We have reviewed the accompanying statement of Un-Audited Standalone Financial Results of **Evexia Lifecare Limited** ("the Company") for the Quarter ended on December 31, 2024, and year to date results for the period from April 01, 2024 to December 31, 2024 ("the Statement") attached herewith. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared pursuant to the requirements Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

## SCOPE OF REVIEW

3. We conducted our review in accordance with the Standards on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of the company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

## CONCLUSION

4. Based on our review conducted as stated in above Paragraph, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard ("Ind AS") specified under section 133 of the Companies Act, 2013 as amended read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in the terms of Listing Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date : 14<sup>th</sup> February 2025

Place : Anand

For, M. A. Shah & Co.

Chartered Accountants

FRN:0112630W



Param Doshi, FCA

(Partner)

Mem. No.: 185648

UDIN : 25185648BMOOLD8286

EVEXIA LIFECARE LIMITED (CIN:L23100GJ1990PLC014692)							
(Regd. Office: VILL : TUNDAO, TAL: SALVI, Vadodara, VADODARA, Gujarat, India, 391775)							
E-mail id: info@evexialifecare.com		Phone: 0265 2361100		website: https://www.evexialifecare.com/			
STATEMENT OF UN-AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2024 (Rs. In Lakhs Except EPS and Face Value of Share)							
	Particulars	Quarter ended			Nine Months ended		Year ended
		December 31, 2024	September 30, 2024	December 31, 2023	April 01, 2024 to December 31, 2024	April 01, 2023 to December 31, 2023	March 31, 2024
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
I	Revenue from operations	2,157.97	2,670.91	674.74	6,870.76	3,124.86	5,489.56
II	Other Income	10.00	0.01	-0.03	10.24	0.09	86.56
III	<b>Total Revenue (I+II)</b>	<b>2,167.97</b>	<b>2,670.92</b>	<b>674.71</b>	<b>6,881.00</b>	<b>3,124.95</b>	<b>5,576.12</b>
IV	<b>Expenses</b>						
	Cost of material consumed	103.86	150.30	2,751.01	264.66	2,841.76	192.70
	Purchase of stock in trade	1,985.50	2,492.06	-2,080.44	6,422.08	21.90	4,810.68
	Changes in inventories of Finished Goods, Work-in-Progress and Stock-in-trade	1.77	-123.33	-44.14	-121.81	-6.85	-1.46
	Employee benefits expenses	18.94	16.75	20.49	53.95	61.69	90.44
	Finance Costs	0.37	4.57	-0.51	4.95	0.50	49.20
	Depreciation depletion and amortization expense	10.68	10.68	6.71	31.48	26.21	41.63
	Other Expenses	20.86	26.09	28.18	70.18	153.27	241.43
	<b>Total Expenses</b>	<b>2,141.98</b>	<b>2,577.12</b>	<b>681.30</b>	<b>6,725.49</b>	<b>3,098.48</b>	<b>5,424.62</b>
V	<b>Profit before exceptional and extraordinary items and tax (III-IV)</b>	<b>25.99</b>	<b>93.80</b>	<b>-6.59</b>	<b>155.51</b>	<b>26.47</b>	<b>151.50</b>
VI	Exceptional Items	-	-	-	-	-	-
VII	<b>Profit before extraordinary items and tax (V-VI)</b>	<b>25.99</b>	<b>93.80</b>	<b>-6.59</b>	<b>155.51</b>	<b>26.47</b>	<b>151.50</b>
VIII	Extraordinary Items	-	-	-	-	-	-
IX	<b>Profit before tax (VII-VIII)</b>	<b>25.99</b>	<b>93.80</b>	<b>-6.59</b>	<b>155.51</b>	<b>26.47</b>	<b>151.50</b>
X	<b>Tax Expenses</b>						
	1) Current tax	-	24.39	-	-	6.88	33.90
	2) Deferred tax	-	-	-	-	-	4.92
	3) Short / (Excess) Provision of Income Tax of Previous Years	-	-	-	-	-	-2.58
XI	<b>Profit (Loss) for the period from continuing operations (IX-X)</b>	<b>25.99</b>	<b>69.41</b>	<b>-6.59</b>	<b>155.51</b>	<b>19.59</b>	<b>115.26</b>
XII	Profit / (Loss) from discontinuing operations	-	-	-	-	-	-
XIII	Tax expenses of discontinuing operations	-	-	-	-	-	-
XIV	<b>Profit / (Loss) from discontinuing operations (after tax) (XII-XIII)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
XV	<b>Total Profit / (Loss) for the period (XI+XIV)</b>	<b>25.99</b>	<b>69.41</b>	<b>-6.59</b>	<b>155.51</b>	<b>19.59</b>	<b>115.26</b>
XVI	<b>Other Comprehensive income</b>						
	A) (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-2.39
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	0.62
	B) (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XVII	<b>Total Comprehensive Income</b>	<b>25.99</b>	<b>69.41</b>	<b>-6.59</b>	<b>155.51</b>	<b>19.59</b>	<b>113.49</b>
XVIII	<b>Paid up Equity Share Capital (Face Value Rs. 1/- each)</b>	<b>18,773.29</b>	<b>14,203.18</b>	<b>6,644.33</b>	<b>18,773.29</b>	<b>6,193.33</b>	<b>7,080.13</b>
XIX	<b>Other Equity excluding Revaluation Reserve</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
XX	<b>Earning per share</b>						
	1) Basic	0.0014	0.0049	-0.0010	0.0083	0.0032	0.0160
	2) Diluted	0.0014	0.0049	-0.0010	0.0083	0.0032	0.0160

DATE:14-02-2025

PLACE: VADODARA



For EVEXIA LIFECARE LIMITED

*Jayesh Raichandbhai Thakkar*  
**JAYESH RAICHANDBHAI THAKKAR**  
 MANAGING DIRECTOR

[DIN:01631093]

**Notes to Stanalone Financial Results - Q3 FY 2024-25**

- 1 The above results which are published have been reviewed and approved by the Board of Directors of the Company at their meeting held on 14th February 2025. The financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules Issued thereunder and the other accounting principles generally accepted In India.) The unaudited financial results for the quarter and Nine Month ended 31st December,2024. have been subjected to limited review by the Statutory Auditors.
- 2 The above consolidated financial results have been reviewed and recommended by Audit Committee and have been approved and taken on record by Board of Directors at its meeting on 14th February 2025.
- 3 The limited review as required under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 has been completed by the auditors of Company.
- 4 Figures for the previous periods have been regrouped and/or rearranged and/or reclassified wherever necessary to make them comparable with those of current periods.

**For EVEXIA LIFECARE LIMITED**



**JAYESH RAICHANDBHAI  
MANAGING DIRECTOR**

**DIN : 01631093**

**DATE: 14.02.2025  
PLACE: VADODARA**

**Limited Review Report on Un-Audited Quarterly Financial Results of Evaxia Lifecare Limited pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 for the Quarter ended on December 31, 2024.**

To

**Board of Directors of  
Evaxia Lifecare Limited**

**INTRODUCTION**

- 1.** We have reviewed the accompanying statement of Un-Audited Consolidated Financial Results of **Evaxia Lifecare Limited** ("the Company") for the Quarter ended on December 31, 2024, and year to date results for the period from April 01, 2024 to December 31, 2024 ("the Statement") attached herewith. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared pursuant to the requirements Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").
- 2.** This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

a



## SCOPE OF REVIEW

3. We conducted our review in accordance with the Standards on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of the company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

## CONCLUSION

4. Based on our review conducted as stated in above Paragraph, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard ("Ind AS") specified under section 133 of the Companies Act, 2013 as amended read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in the terms of Listing Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Date:** 14<sup>th</sup> February 2025

**Place:** Anand

**For, M. A. Shah & Co.**

Chartered Accountants

FRN: 0112630W



**Param Doshi, FCA**

(Partner)

Mem. No.: 185648

UDIN : 25185648BMOOLD8286



EVEXIA LIFECARE LIMITED							
(CIN:L23100GJ1990PLC014692 )							
(Regd. Office: VILL : TUNDAO, TAL: SALVI, Vadodara, VADODARA, Gujarat, India, 391775 )							
E-mail id: info@evexialifecare.com		Phone: 0265 2361100		website: https://www.evexialifecare.com/			
STATEMENT OF UN-AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2024							
(Rs. In Lakhs Except EPS and Face Value of Share)							
		Quarter Ended			Nine Months ended		Year ended
		December 31, 2024	September 30, 2024	December 31, 2023	April 01, 2024 to December 31, 2024	April 01, 2023 to December 31, 2023	March 31, 2024
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
I	Revenue from operations	2,169.97	2,670.91	674.74	7,089.67	3,124.86	5,628.90
II	Other Income	10.00	0.01	(0.03)	28.13	0.09	86.56
III	<b>Total Revenue (I+II)</b>	<b>2,179.97</b>	<b>2,670.92</b>	<b>674.71</b>	<b>7,117.80</b>	<b>3,124.95</b>	<b>5,715.46</b>
IV	<b>Expenses</b>						
	Cost of material consumed	103.86	150.30	2,751.01	264.66	2,841.76	192.70
	Purchase of stock in trade	1,997.50	2,492.06	(2,080.44)	6,632.76	21.90	4,847.82
	Changes in inventories of Finished Goods, Work-in-Progress and Stock-in-trade	1.77	(123.33)	(44.14)	-107.13	(6.85)	24.39
	Employee benefits expenses	18.94	16.75	20.49	53.95	61.69	94.41
	Finance Costs	0.38	4.57	(0.51)	5.70	0.50	49.20
	Depreciation , Depletion and amortization expense	10.68	10.68	6.71	31.48	26.21	41.63
	Other Expenses	30.96	26.09	28.18	89.80	153.27	272.40
	<b>Total Expenses</b>	<b>2,164.09</b>	<b>2,577.12</b>	<b>681.30</b>	<b>6,971.22</b>	<b>3,098.48</b>	<b>5,522.55</b>
V	<b>Profit before exceptional and extraordinary items and tax (III-IV)</b>	<b>15.88</b>	<b>93.80</b>	<b>(6.59)</b>	<b>146.57</b>	<b>26.47</b>	<b>192.91</b>
VI	Exceptional Items	-	-	-	-	-	-
VII	<b>Profit before extraordinary items and tax (V-VI)</b>	<b>15.88</b>	<b>93.80</b>	<b>-6.59</b>	<b>146.57</b>	<b>26.47</b>	<b>192.91</b>
VIII	Extraordinary items	-	-	-	-	-	-
IX	<b>Profit before tax (VII-VIII)</b>	<b>15.88</b>	<b>93.80</b>	<b>-6.59</b>	<b>146.57</b>	<b>26.47</b>	<b>192.91</b>
X	Tax Expenses						
	1) Current tax	4.13	24.39	(1.71)	38.11	6.88	52.87
	2) Deferred tax	-	-	-	-	-	4.92
	3) Short / (Excess) Provision of Income Tax of Previous Years	-	-	-	-	-	(2.58)
XI	<b>Profit (Loss) for the period from continuing operations (IX-X)</b>	<b>11.75</b>	<b>69.41</b>	<b>(4.88)</b>	<b>108.47</b>	<b>19.59</b>	<b>137.70</b>
XII	<b>Profit / (Loss) from discontinuing operations</b>	-	-	-	-	-	-
XIII	Tax expenses of discontinuing operations	-	-	-	-	-	-
XIV	Profit / (Loss) from discontinuing operations (after tax) (XII-XIII)	-	-	-	-	-	-
	Share of Profit/ (Loss) of Associates and Joint Ventures accounted for using equity method	-	-	-	-	-	-
XV	<b>Net Profit / (Loss) for the period (XI+XIV)</b>	<b>11.75</b>	<b>69.41</b>	<b>(4.88)</b>	<b>108.47</b>	<b>19.59</b>	<b>137.70</b>
XVI	<b>Other Comprehensive income</b>						
	A) (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B) (i) Items that will be reclassified to profit or loss	-	-	-	-	-	(1.77)
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XVII	<b>Total Comprehensive Income</b>	<b>11.75</b>	<b>69.41</b>	<b>(4.88)</b>	<b>108.47</b>	<b>19.59</b>	<b>139.47</b>
XVIII	<b>Paid up Equity Share Capital (Face Value Rs. 1/- each)</b>	<b>18,773.29</b>	<b>14,203.18</b>	<b>6,644.33</b>	<b>18,773.29</b>	<b>6,193.33</b>	<b>7,080.13</b>
XIX	<b>Other Equity excluding Revaluation Reserve</b>	-	-	-	-	-	-
XX	<b>Earning per share</b>						
	1) Basic	0.0006	0.0049	(0.0007)	0.0058	0.0032	0.0210
	2) Diluted	0.0006	0.0049	(0.0007)	0.0058	0.0032	0.0210

DATE:14-02-2025  
PLACE: VADODARA



For EVEXIA LIFECARE LIMITED  
*Jayesh Rajchandbhai Thakkar*  
JAYESH RAJCHANDBHAI THAKKAR  
MANAGING DIRECTOR  
[DIN:01631093]

**Notes to Consolidated Financial Results - Q3 FY 2024-25**

- 1 The above results which are published have been reviewed and approved by the Board of Directors of the Company at their meeting held on 14th February 2025. The financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules Issued thereunder and the other accounting principles generally accepted In India.) The unaudited financial results for the quarter and Nine Month ended 31st December,2024. have been subjected to limited review by the Statutory Auditors.
- 2 The above consolidated financial results have been reviewed and recommended by Audit Committee and have been approved and taken on record by Board of Directors at its meeting on 14th February 2025.
- 3 The limited review as required under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 has been completed by the auditors of Company.
- 4 Figures for the previous periods have been regrouped and/or rearranged and/or reclassified wherever necessary to make them comparable with those of current periods.



**For EVEXIA LIFECARE LIMITED**

A handwritten signature in blue ink, appearing to read "Jayesh Raichandbhai Thakkar".

**JAYESH RAICHANDBHAI THAKKAR  
MANAGING DIRECTOR**

**DIN : 01631093**

**DATE: 14.02.2025  
PLACE: VADODARA**



EVEXIA LIFECARE LIMITED

(Formerly Known as Kavit Industries Ltd.)

**STATEMENT OF DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT**

Statement on deviation / variation in utilization of funds raised			
Name of listed entity	Evexia Lifecare Limited		
Mode of Fund Raising	Preferential Issue of Convertible Warrants		
Date of Raising Funds	November 13,2024		
Amount Raised	Issue Size:- 86,40,00,000		
Report filed for Quarter ended	December 31,2024		
Monitoring Agency	Not Applicable		
Monitoring Agency Name, if Applicable	Not Applicable		
Is there a Deviation / Variation in use of funds raised	No		
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	N.A.		
If Yes, Date of shareholder Approval	N.A.		
Explanation for the Deviation / Variation	N.A.		
Comments of the Audit Committee after review	Nil		
Objects for which funds have been raised and where there has been a deviation, in the following table:			
Sr. No.	Particulars (Object of the Issue)	Total estimated amount to be utilised for each of the Objects* (Rs. In crore)	Tentative timelines for utilization of Issue Proceeds from the date of receipt of funds
1	Capital Expansion requirement	25.00 Crores	Within 12 months from receipt of the Issue Proceeds (as set out herein)
2	Working capital requirement	41.40 Crores	
3	General Corporate Purpose	20.00 Crores	
	<b>Total</b>	86.40 Crores	

**Deviation or variation could mean:**

Reg. Off. : Tundav Anjesar Raod, Vill. Tundav, Tal.: Savli, Vadodara - 391 775

Corporate Office : 9th Floor, Galav Chambers, Sayajigunj, Vadodara-390 020. Ph : +91 265 2361100 / 2200

CIN : L23100GJ1990PLC014692 Email : info@evexialifecare.com Web.: www.evexialifecare.com



**EVEXIA LIFECARE LIMITED**

(Formerly Known as Kavit Industries Ltd.)

- (a) Deviation in the objects or purposes for which the funds have been raised or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
- (c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc.

**FOR, EVEXIA LIFECARE LIMITED**

---

**JAYESH RAICHANDBHAI THAKKAR**  
**MANAGING DIRECTOR**  
**(DIN: 01631093)**

---

**Reg. Off. :** Tundav Anjesar Raod, Vill. Tundav, Tal.: Savli, Vadodara - 391 775

**Corporate Office :** 9th Floor, Galav Chambers, Sayajigunj, Vadodara-390 020. **Ph :** +91 265 2361100 / 2200

**CIN :** L23100GJ1990PLC014692 **Email :** info@evexialifecare.com **Web.:** www.evexialifecare.com